Phaseline

Targets › NCBP1

NCBP1 (Nuclear cap-binding protein subunit 1): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Immunology, Other; next expected readout Dec 2026.

Component of the cap-binding complex (CBC), which binds cotranscriptionally to the 5'-cap of pre-mRNAs and is involved in various processes such as pre-mRNA splicing, translation regulation, nonsense-mediated mRNA decay, RNA-mediated gene silencing (RNAi) by microRNAs (miRNAs) and mRNA export. The CBC complex is involved in mRNA export from the nucleus via its interaction with ALYREF/THOC4/ALY, leading to the…. (UniProt, Q09161)

Open in Phaseline: the race on NCBP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AbivaxObefazimod (ABX464)
Cap binding complex modulator
NCBP2, NCBP1Phase 3Ulcerative Colitis; Moderately to Severely Active Crohn Disease; HealthyDec 2026

Conditions

Ulcerative Colitis (2) Moderately to Severely Active Crohn Disease (1) Healthy (1)

Modalities

small molecule (1)

Companies

Abivax (1)

Related targets

NCBP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.